XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues
Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:
Three Months Ended
March 31,
20232022
Biogen MA, Inc.84 %40 %
Kite Pharma, Inc.8 %22 %
Novartis Institutes for BioMedical Research, Inc.6 %32 %
Sanofi S.A.— %5 %
Schedule of Cash and Cash Equivalents A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):
March 31,
2023		December 31,
2022		March 31,
2022		December 31,
2021
Cash and cash equivalents$78,241 $100,444 $120,257 $178,872 
Non-current restricted cash1,500 1,500 1,500 1,500 
Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows$79,741 $101,944 $121,757 $180,372 
Restrictions on Cash and Cash Equivalents A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):
March 31,
2023		December 31,
2022		March 31,
2022		December 31,
2021
Cash and cash equivalents$78,241 $100,444 $120,257 $178,872 
Non-current restricted cash1,500 1,500 1,500 1,500 
Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows$79,741 $101,944 $121,757 $180,372